Cargando…
Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
OBJECTIVE: To compare outcomes after treatment with autologous haematopoietic stem cell transplantation (AHSCT) and alemtuzumab (ALZ) in patients with relapsing–remitting multiple sclerosis. METHODS: Patients treated with AHSCT (n=69) received a conditioning regimen of cyclophosphamide (200 mg/kg) a...
Autores principales: | Zhukovsky, Christina, Sandgren, Sofia, Silfverberg, Thomas, Einarsdottir, Sigrun, Tolf, Andreas, Landtblom, Anne-Marie, Novakova, Lenka, Axelsson, Markus, Malmestrom, Clas, Cherif, Honar, Carlson, Kristina, Lycke, Jan, Burman, Joachim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841472/ https://www.ncbi.nlm.nih.gov/pubmed/33106366 http://dx.doi.org/10.1136/jnnp-2020-323992 |
Ejemplares similares
-
The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective survey
por: Sandgren, Sofia, et al.
Publicado: (2023) -
A real‐world study of alemtuzumab in a cohort of Italian patients
por: Russo, Cinzia Valeria, et al.
Publicado: (2021) -
Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT
por: Kvistad, Silje Agnethe Stokke, et al.
Publicado: (2022) -
Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021) -
Autologous haematopoietic stem cell transplantation versus low‐dose immunosuppression in secondary–progressive multiple sclerosis
por: Mariottini, Alice, et al.
Publicado: (2022)